Clinical trial
Safety of RG2077 in Patients With Multiple Sclerosis
NCT00076934 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00076934 |
|---|---|
| Title | Safety of RG2077 in Patients With Multiple Sclerosis |
| Official title | A Phase I Study: Safety of RG2077 (CTLA4-IgG4m) in Patients With Relapsing-Remitting Multiple Sclerosis |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Immune Tolerance Network (ITN) Repligen Corporation Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis, Relapsing-Remitting |
| Intervention type | Drug |
| Interventions | RG2077 (CTLA4-IgG4m) |
| Enrollment | 20 |
| Start date | Jan 1, 2003 |
| Completion | Feb 1, 2006 |
| First posted | Feb 9, 2004 |
| Last update posted | Mar 27, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: